COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN COMPARED TO WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN A MEDICARE POPULATION

被引：0
|
作者：
Ward, M. A. [1 ]
Biddle, A. K. [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.657
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A121 / A121
页数：1
相关论文
共 50 条
  • [31] Is Dabigatran Cost Effective Compared With Warfarin for Stroke Prevention in Atrial Fibrillation? A Critically Appraised Topic
    Adcock, Amelia K.
    Lee-Iannotti, Joyce K.
    Aguilar, Maria I.
    Hoffman-Snyder, Charlene R.
    Wingerchuk, Dean M.
    Wellik, Kay E.
    Demaerschalk, Bart M.
    NEUROLOGIST, 2012, 18 (02) : 102 - 107
  • [32] A COST-EFFECTIVENESS ANALYSIS COMPARING DABIGATRAN AND STANDARD TREATMENT FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN SLOVAKIA
    Psenkova, M.
    Mackovicova, S.
    Tomek, D.
    Bielik, J.
    Spitzerova, H.
    VALUE IN HEALTH, 2012, 15 (04) : A121 - A121
  • [33] Cost-Effectiveness of Apixaban Compared With Aspirin for Stroke Prevention in Atrial Fibrillation Among Patients Unsuitable for Warfarin
    Lee, Soyon
    Anglade, Moise W.
    Meng, Joy
    Hagstrom, Kelly
    Kluger, Jeffrey
    Coleman, Craig I.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2012, 5 (04): : 472 - 479
  • [34] COST-EFFECTIVENESS OF APIXABAN COMPARED TO ASPIRIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
    Lee, Soyon
    Anglade, Moise
    Hagstrom, Kelly
    Meng, Joy
    Kluger, Jeffrey
    Coleman, Craig
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E596 - E596
  • [35] Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation
    Kamel, Hooman
    Easton, J. Donald
    Johnston, S. Claiborne
    Kim, Anthony S.
    NEUROLOGY, 2012, 79 (14) : 1428 - 1434
  • [36] Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation
    You, Joyce H. S.
    Tsui, Kia K. N.
    Wong, Raymond S. M.
    Cheng, Gergory
    PLOS ONE, 2012, 7 (06):
  • [37] COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE COMPARED TO RIVAROXABAN FOR PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH ATRIAL FIBRILLATION IN CHINA
    Dong, S.
    Wu, B.
    Zhai, S.
    Zhang, Y.
    Chu, Y.
    Gupta, P.
    Li, Y.
    VALUE IN HEALTH, 2018, 21 : S62 - S62
  • [38] COST-EFFECTIVENESS OF DABIGATRAN VERSUS WARFARIN IN ATRIAL FIBRILLATION MANAGEMENT IN COLOMBIA
    Alfonso-Cristancho, R.
    Herran, S.
    Caicedo, M.
    Gomez, E.
    VALUE IN HEALTH, 2011, 14 (07) : A536 - A537
  • [39] A Comparison of Dabigatran With Warfarin for Stroke Prevention in Atrial Fibrillation in an Asian Population
    Bin Yap, Lok
    Eng, Daniel Theng Sheng
    Sivalingam, Lingghesh
    Rusani, Beni Isman
    Umadevan, Dhanan
    Muhammad, Zulkeflee
    Koh, Kok Wei
    Aisha, Barveen
    Hashim, Mohd Irwan
    Rebo, Rosila
    Hussin, Azlan
    Kaur, Surinder
    Shanmugam, Rajasingam
    Omar, Razali
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2016, 22 (08) : 792 - 797
  • [40] Improve Warfarin Therapy or Use Dabigatran for Patients with Atrial Fibrillation - A Cost-Effectiveness Analysis
    You, Joyce H.
    Tsui, Kia K.
    Wong, Raymond S.
    Cheng, Gregory
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (09): : 1334 - 1334
12345